[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353852-105":59,"doc-detail-353852-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","modulation-of-oncogenic-notch-signaling-in-highly-aggressive-malignancies-by-targeting-the-secretase-complex-a-systematic-review","Modulation of Oncogenic NOTCH Signaling in Highly Aggressive Malignancies by Targeting the γ-Secretase Complex - A Systematic Review","","NOTCH receptors are central to carcinogenesis through ligand-driven proteolytic cleavages mediated by ADAM proteases and the γ-secretase complex, culminating in NICD nuclear signaling. This systematic review evaluates γ-secretase inhibitors (GSIs) as anticancer agents across preclinical and clinical settings, emphasizing blockade of tumor progression, effects on cancer stem cells, and resistance overcoming. Searches in ISI Web of Science, PubMed, and Scopus under PRISMA identified 69 eligible studies across NSCLC, TNBC, metastatic melanoma, PDAC, and gastric cancer. Findings support therapeutic synergy with chemotherapy/radiotherapy, EMT inhibition, resistance reduction, and improved prognosis, while highlighting limited clinical evidence and toxicity constraints.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/modulation-of-oncogenic-notch-signaling-in-highly-aggressive-malignancies-by-targeting-the-secretase-complex-a-systematic-review/353852/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/modulation-of-oncogenic-notch-signaling-in-highly-aggressive-malignancies-by-targeting-the-secretase-complex-a-systematic-review/353852.png","ImageObject",300,407,{"name":92,"@type":93},"Margaret","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does the NOTCH signaling pathway play in cancer according to the review?","Question",{"text":112,"@type":113},"NOTCH receptors regulate carcinogenesis via ligand-induced proteolytic cleavages that activate NICD, which then translocates to the nucleus to regulate gene expression and downstream oncogenic programs.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the authors conduct the systematic review and select studies?",{"text":117,"@type":113},"A systematic search was performed in ISI Web of Science, PubMed, and Scopus following PRISMA guidelines, and inclusion covered preclinical in vitro/in vivo studies and clinical trials of GSIs in specified cancer types while excluding duplicates, non-English articles, pre-2010 work, noncancer studies, unrelated research, and studies outside the selected cancers.",{"name":119,"@type":110,"acceptedAnswer":120},"What are the main conclusions about γ-secretase inhibitors for aggressive cancers?",{"text":121,"@type":113},"GSIs show promising antitumor activity in vitro and in mouse xenograft models, can synergize with chemotherapy and radiotherapy, may block EMT and overcome resistance, and are linked to improved prognosis in preclinical data; however, clinical trial evidence remains limited and toxicity/tolerability issues constrain use.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353852,1790897422,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":24,"preview_urls":146},137451207643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Systematic Review  \nModulation of Oncogenic NOTCH Signaling in Highly Aggressive Malignancies by Targeting the γ-Secretase Complex: A Systematic Review  \nPablo Martínez-Gascueña 1, María-Luisa Nueda 2 and Victoriano Baladrón 3, *  \nAcademic Editor: Dooil Jeoung  \nReceived: 22 December 2025  \nRevised: 23 February 2026  \nAccepted: 3 March 2026  \nPublished: 5 March 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Servicio de Cardiología, Hospital Clínico San Carlos, C/del Profesor Martín Lagos, S/N, Moncloa-Aravaca, 29040 Madrid, Spain; [pgascu@outlook.es](pgascu@outlook.es)  \n2 Área de Bioquímica y Biología Molecular, Departamento de Química Inorgánica, Orgánica y Bioquímica, Facultad de Farmacia/IB-UCLM/Unidad de Biomedicina/IDISCAM, Universidad de Castilla-La Mancha/CSIC/SESCAM, C/Dr. José María Sánchez Ibáñez, S/N, 02071 Albacete, Spain; [marialuisa.nueda@uclm.es](marialuisa.nueda@uclm.es)  \n3 Área de Bioquímica y Biología Molecular, Departamento de Química Inorgánica, Orgánica y Bioquímica, Facultad de Medicina de Albacete/IB-UCLM/Unidad de Biomedicina/IDISCAM, Universidad de Castilla-La Mancha/CSIC/SESCAM, C/Almansa 14, 02008 Albacete, Spain  \n* Correspondence: victoriano.baladron@uclm.es; Tel.: +34-926-053-663 or +34-679-152-476  \nHighlights  \nWhat are the main findings?  \n• γ-secretase inhibitors (GSIs) and other alternative strategies demonstrate promising antitumor activity in vitro and in mouse xenograft models, potentiating the effects of chemotherapy and radiotherapy, and helping overcome therapy resistance and improve patient prognosis.  \n• Some GSIs may also exhibit dose-and time-dependent influences on the tumor’soncogenic properties. However, despite encouraging preclinical findings, clinical trial results remain limited.  \nWhat are the implications of the main findings?  \n• The broad inhibition of the NOTCH pathway by GSIs can unintentionally suppress tumor-suppressive NOTCH receptors (such as NOTCH2 in certain breast cancer subtypes) . Moreover, partial, or low-level pathway inhibition may paradoxically promote cellular proliferation, leading to unpredictable therapeutic outcomes. For these reasons, next-generation approaches should focus on developing receptor-specific GSIsor alternative NOTCH-targeting agents (e.g., DLK1/DLK2 modulators) . The use of cell lines with artificially overactivated NOTCH signaling may not fully reflect the heterogeneity of human tumors, and GSIs may only target specific cellular subpopulations. In clinical settings, their application has been limited by significant toxicity and poor tolerability.  \n• Future research should further investigate microenvironment-driven mechanisms of drug resistance, including EMT, invasion, and stromal interactions. A deeper understanding of immune-evasion strategies could improve immunotherapy efficacy. In parallel, anti-angiogenic approaches should be prioritized as key therapeutic strategies. Advanced therapeutic modalities, such as CRISPR-based editing, CAR T-cell therapy, bispecific antibodies, and nanoparticle-mediated targeted delivery, may enhance treatment precision while reducing toxicity. Targeting cancer stem cells remains a central objective. Treatment optimization should incorporate patient stratification based on NOTCH receptor and ligand expression, pathway activation status, and immune antigen profiles. Emerging tools such as AI and big-data analytics will support  \nthe personalization of cancer therapies and should account for sex-specific biological differences to maximize therapeutic efficacy.  \nAbstract  \nBackground. NOTCH receptors play a pivotal role in carcinogenesis. Upon ligand binding, a cascade of proteolytic cleavages mediated by ADAM proteases and the γ-secretase complex activates the receptor, ultimately releasing the NOTCH intracellular domain (NICD) . NICD","cbCaimKgkrsbxIPW","https://ap.wps.com/l/cbCaimKgkrsbxIPW","pdf",2473001,49,"English","# Highlights\n## Main findings\n## Implications of main findings\n# Abstract\n## Background\n## Methods\n## Findings and results","[{\"question\":\"What role does the NOTCH signaling pathway play in cancer according to the review?\",\"answer\":\"NOTCH receptors regulate carcinogenesis via ligand-induced proteolytic cleavages that activate NICD, which then translocates to the nucleus to regulate gene expression and downstream oncogenic programs.\"},{\"question\":\"How did the authors conduct the systematic review and select studies?\",\"answer\":\"A systematic search was performed in ISI Web of Science, PubMed, and Scopus following PRISMA guidelines, and inclusion covered preclinical in vitro/in vivo studies and clinical trials of GSIs in specified cancer types while excluding duplicates, non-English articles, pre-2010 work, noncancer studies, unrelated research, and studies outside the selected cancers.\"},{\"question\":\"What are the main conclusions about γ-secretase inhibitors for aggressive cancers?\",\"answer\":\"GSIs show promising antitumor activity in vitro and in mouse xenograft models, can synergize with chemotherapy and radiotherapy, may block EMT and overcome resistance, and are linked to improved prognosis in preclinical data; however, clinical trial evidence remains limited and toxicity/tolerability issues constrain use.\"}]","Modulation of Oncogenic NOTCH Signaling in Highly Aggressive Malignancies by Targeting the γ-Secretase Complex - A Systematic Review | PDF",1790107566,123,[147,151,155,159,163],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33778842a52318b97fde6f2d6eed9a1f.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/875220697c064b49c01a200dde5e44fd.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/03550d1940a8c05133509082cfd62ea9.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6eec94cb38c64078009ca44302b26979.webp",980,1385,{"page_no":24,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b952d82612c954fec63d1c921846e540.webp",979,1384]